Section 128: Advanced Myelin Repair and Remyelination Therapy in CBS/PSP

Section 128: Advanced Myelin Repair and Remyelination Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 128: Advanced Myelin Repair and Remyelination Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Clemastine</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Opicinumab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Ibudilast</td>
<td>MediciNova</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Clemastine</td>
<td>M1 receptor</td>
</tr>
<tr>
<td class="label">Opicinumab</td>
<td>LINGO-1</td>
</tr>
<tr>
<td class="label">Ibudilast</td>
<td>PDE4</td>
</tr>
<tr>
<td class="label">OPC transplant</td>
<td>Cell replacement</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Trophic factors</td>
</tr>
</table>

Section 128: Advanced Myelin Repair and Remyelination Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 128: Advanced Myelin Repair and Remyelination Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Clemastine</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Opicinumab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Ibudilast</td>
<td>MediciNova</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Clemastine</td>
<td>M1 receptor</td>
</tr>
<tr>
<td class="label">Opicinumab</td>
<td>LINGO-1</td>
</tr>
<tr>
<td class="label">Ibudilast</td>
<td>PDE4</td>
</tr>
<tr>
<td class="label">OPC transplant</td>
<td>Cell replacement</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Trophic factors</td>
</tr>
</table>

Myelin repair and remyelination represent a critical but often overlooked therapeutic frontier in neurodegenerative diseases, including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). While traditionally considered white matter disorders, emerging evidence demonstrates that oligodendrocyte dysfunction and myelin pathology contribute substantially to the neurodegenerative process in 4R-tauopathies[@ferrer2014]. The presence of oligodendrocyte inclusion (OI) bodies containing hyperphosphorylated tau, alongside white matter abnormalities on MRI, suggests that addressing myelin dysfunction may provide clinical benefit.

This section provides comprehensive coverage of advanced myelin repair strategies, focusing on oligodendrocyte precursor cell (OPC) activation, pharmacologic remyelination approaches including clemastine and opicinumab, LINGO-1 inhibition, and neurophysiological assessment tools like the Negative Equilibration Test (NET) for monitoring treatment response.

1. Oligodendrocyte Dysfunction in CBS/PSP

1.1 Pathological Role of Oligodendrocytes

Oligodendrocytes are the myelin-producing cells of the central nervous system, and their dysfunction contributes to neurodegeneration through multiple mechanisms:

Primary Pathologies:

• Oligodendrocyte Inclusion Bodies: PSP brains frequently contain coiled bodies and other tau-positive inclusions within oligodendrocytes, disrupting their normal function[@kovacs2019]
• White Matter Degeneration: Post-mortem studies demonstrate widespread white matter abnormalities in PSP, including loss of oligodendrocytes and myelin breakdown
• Iron Accumulation: Oligodendrocytes are particularly susceptible to iron-mediated oxidative damage, which is加重ated in PSP

• Axonal dysfunction due to myelin breakdown
• Reduced conduction velocity in affected pathways
• Energy deprivation of axons due to impaired oligodendrocyte support
• Increased vulnerability to secondary excitotoxic injury

1.2 Oligodendrocyte Precursor Cells (OPCs)

OPC (also known as NG2-positive cells) are resident stem cells in the adult CNS capable of differentiating into mature oligodendrocytes:

• OPCs constitute 5-10% of all cells in adult human white matter
• They remain proliferative throughout life and can respond to demyelination
• However, in chronic neurodegenerative conditions, OPC differentiation becomes impaired
• Multiple factors contribute to OPC "paralysis": inflammatory environment, trophic factor deficiency, and intrinsic signaling dysregulation

1.3 Rationale for Remyelination Therapy in CBS/PSP

The therapeutic rationale for myelin repair in CBS/PSP includes:

2. Clemastine: The Anti-Allergic Remyelination Agent

2.1 Discovery and Mechanism

Clemastine fumarate, an FDA-approved antihistamine with anticholinergic properties, was serendipitously identified as a potent promoter of OPC differentiation and remyelination in high-throughput drug screens[@mei2014].

Mechanism of Action:
Clemastine promotes remyelination through multiple mechanisms:

• M1 muscarinic receptor antagonism: Blocks inhibitory M1 signaling in OPCs, relieving differentiation block
• Enhanced OPC differentiation: Promotes transition from proliferative OPCs to mature oligodendrocytes
• Improved myelination: Increases the efficiency of myelin sheath formation
• Anti-inflammatory effects: Reduces pro-inflammatory cytokine production

2.2 Clinical Evidence

Phase 2 Trial (CELLO):

• Randomized, double-blind, placebo-controlled trial in relapsing-remitting MS
• Oral clemastine (80 mg daily) vs placebo for 4 months
• Primary endpoint: Visual evoked potential (VEP) latency improvement
• Results: Significant reduction in VEP latency (p=0.004), indicating improved conduction
• Secondary endpoints: Patient-reported fatigue improvement

• First demonstration of functional remyelination in humans with a drug
• Well-tolerated at doses up to 80 mg daily
• Expected anticholinergic side effects (dry mouth, constipation) were mild
• No significant cognitive impairment at the doses used

2.3 Application to CBS/PSP

While clemastine has been studied primarily in multiple sclerosis, the mechanism is relevant to CBS/PSP:

Potential Benefits:

• OPC activation may help replace dysfunctional oligodendrocytes
• Improved conduction in corticospinal tract and other white matter tracts
• Reduced axonal degeneration through improved metabolic support

• CBS/PSP involve primary oligodendrocyte tau pathology, not just demyelination
• The chronic, progressive nature may limit OPC response
• Need for biomarker evidence of white matter involvement

• Optimal dosing for CNS disease needs clarification
• Combination with other remyelination agents may be required
• Long-term safety in elderly patients with CBS/PSP

3. Opicinumab: Anti-LINGO-1 Antibody

3.1 LINGO-1 Biology

LINGO-1 (Leucine-rich repeat and immunoglobulin-like domain-containing neurite outgrowth inhibitor protein 1) is a transmembrane protein expressed primarily on OPCs and neurons that negatively regulates:

• OPC differentiation and myelination
• Neurite outgrowth and neuronal survival
• Axonal integrity

• High expression on OPCs during development (silenced in adult)
• Re-expression in demyelinating lesions
• Also expressed on neurons, particularly in white matter tracts

3.2 Opicinumab Mechanism

Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 designed to block its inhibitory function:

Mechanism:

• Binds to LINGO-1 extracellular domain
• Prevents LINGO-1 interaction with its partners (NgR1, p75, TROY)
• Relieves inhibition on OPC differentiation
• Promotes myelination
• May provide neuroprotective effects through neuronal LINGO-1 blockade

3.3 Clinical Development

Phase 2 Trials (SYNERGY, ASCEND):

• Tested opicinumab in relapsing-remitting MS and acute optic neuritis
• Dose-ranging: 3, 10, 30, 100 mg/kg IV monthly
• Primary endpoints: Evoked potential measures, MRI metrics

• Mixed results across trials
• Post-hoc analysis showed potential benefit in subgroups
• No clear significant benefit in primary analyses
• Generally well-tolerated

• Development paused pending further analysis
• Biomarker studies ongoing to identify responsive populations
• Potential for combination therapy with other remyelination agents

3.4 Relevance to CBS/PSP

Theoretical Benefits:

• May promote OPC-mediated replacement of tau-laden oligodendrocytes
• Potential neuroprotective effects through neuronal LINGO-1 blockade
• Could improve conduction in affected white matter tracts

• Mechanism primarily validated in MS demyelination models
• Primary oligodendrocyte degeneration in CBS/PSP may not respond as well
• Need for patient selection based on white matter involvement biomarkers

4. Other Remyelination Strategies

4.1 Small Molecule Approaches

Benztropine: Another antihistamine with remyelination properties:

• Similar mechanism to clemastine (M1 antagonist)
• Promotes OPC differentiation in vitro and in vivo
• Being investigated for combination approaches

• Promotes OPC differentiation through different mechanisms
• Being optimized for CNS penetration

• Reduces inflammatory demyelination
• May enhance endogenous remyelination

4.2 Cell-Based Approaches

OPC Transplantation:

• Autologous OPC transplantation being explored
• Genetic modification to enhance survival and differentiation
• Combination with supportive matrices

• Patient-specific OPC therapy
• Immune-matched allogeneic approaches
• Clinical trials expected in coming years

4.3 Gene Therapy Approaches

Overexpression of Trophic Factors:

• PDGF-AA delivery to support OPC survival
• CNTF delivery for oligodendrocyte maturation
• AAV-mediated gene therapy approaches

• LINGO-1 knockdown via siRNA
• CRISPR-based approaches to enhance OPC function

5. Neurophysiological Assessment: The Negative Equilibration Test (NET)

5.1 Background

The Negative Equilibration Test (NET) is a neurophysiological assessment designed to evaluate the functional integrity of white matter conduction pathways[@leocani2003]. While not specific to myelin, it provides an objective measure of conduction velocity that can be used to monitor remyelination therapies.

5.2 Method

Procedure:

Interpretation:

• Increased latency indicates slowed conduction (demyelination)
• Improvement in latency suggests remyelination or functional recovery
• Can be applied to various pathways: corticospinal, sensory, visual

5.3 Application to CBS/PSP

Utility in CBS/PSP:

• Baseline assessment of corticospinal tract function
• Monitoring disease progression
• Objective measure of therapeutic response

• Requires patient cooperation
• Limited spatial resolution
• Not specific to demyelination vs. axonal loss

5.4 Complementary Assessments

Visual Evoked Potentials (VEP):

• Standard test of visual pathway conduction
• Used in MS remyelination trials
• Can be applied to CBS/PSP with visual pathway involvement

• Assesses dorsal column function
• Sensitive to white matter abnormalities

• Cortical excitability
• Central motor conduction time
• Non-invasive assessment of corticospinal integrity

6. Biomarkers for Myelin Health

6.1 Imaging Biomarkers

MRI Metrics:

• T2-weighted imaging: White matter hyperintensities
• Magnetization Transfer Ratio (MTR): Myelin content
• Diffusion Tensor Imaging (DTI): White matter integrity
• Myelin Water Imaging: Quantitative myelin measurement
• PET radiotracers: Emerging myelin-specific tracers

• Abnormalities in corticospinal tract
• Periventricular white matter changes
• Correlation with clinical severity

6.2 Fluid Biomarkers

Myelin-Related Proteins:

• Myelin basic protein (MBP): Marker of myelin breakdown
• Myelin oligodendrocyte glycoprotein (MOG): Surface myelin protein
• Oligodendrocyte-specific proteins

• Axonal injury marker
• Elevated in CBS/PSP
• Correlates with disease progression

6.3 Clinical Outcome Measures

Functional Scales:

• Timed Walk Test
• 9-Hole Peg Test
• Box and Block Test
• Grip strength

• Multiple Sclerosis Functional Composite (MSFC)
• PSP Rating Scale (PSPRS) - adapted components

7. Combination Approaches

7.1 Rationale for Combination Therapy

Given the complex pathogenesis of myelin dysfunction in CBS/PSP, combination approaches may be necessary:

Mechanistic Synergy:

• Clemastine + Opicinumab: Different mechanisms (M1 blockade + LINGO-1 inhibition)
• Remyelination + Neuroprotection: Addressing both oligodendrocyte function and neuronal survival
• Anti-inflammatory + Promyelination: Reducing hostile environment while promoting repair

7.2 Emerging Combinations

Clemastine + Ibudilast:

• Dual mechanism: OPC activation + anti-inflammatory
• Currently in clinical testing

• T-cell modulators combined with remyelination promotion
• Reduces hostile environment for OPCs

• OPC transplantation with trophic factor support
• Enhanced engraftment and differentiation

7.3 Treatment Algorithm

Proposed Approach for CBS/PSP:

• MRI with quantitative metrics
• Neurophysiological testing (VEP, SSEP, NET)
• Fluid biomarkers

• Evidence of white matter involvement
• Preserved OPC population (via MRI)
• Active disease stage

• Clemastine as first-line (approved, well-tolerated)
• Consider opicinumab in selected patients
• Consider combination in refractory cases

• Quantitative MRI every 6 months
• Neurophysiological testing
• Clinical outcome measures

8. Clinical Trial Landscape

8.1 Active Trials in Remyelination

8.2 CBS/PSP-Specific Considerations

Patient Selection:

• MRI evidence of white matter involvement
• Clinical evidence of corticospinal tract dysfunction
• Relatively preserved functional status

• Quantitative MRI (MTR, DTI)
• Neurophysiological measures (VEP, NET)
• Clinical rating scales

• Randomized, placebo-controlled
• Minimum 12-month duration
• Biomarker-driven patient selection

8.3 Challenges

• Heterogeneity: Variable white matter involvement in CBS/PSP
• Chronicity: Long-standing oligodendrocyte dysfunction may be less responsive
• Biomarkers: Need for validated myelin-specific biomarkers
• Endpoints: Clinical scales less sensitive to white matter changes

9. Future Directions

9.1 Promising Approaches

• Enhanced antibody delivery: Brain-penetrant versions of anti-LINGO-1
• Gene therapy: AAV-delivered trophic factors for OPC support
• Cell therapy: Autologous or allogeneic OPC transplantation
• Personalized approaches: Patient selection based on biomarker profiles

9.2 Research Priorities

9.3 Key Research Questions

• What is the relative contribution of primary oligodendrocyte pathology vs. secondary demyelination in CBS/PSP?
• Can chronically impaired OPCs be reactivated?
• What determines responsiveness to remyelination therapies?
• Will remyelination translate to clinical benefit in CBS/PSP?

See Also

• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
• [Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies-cbs-psp)
• [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
• [White Matter Disorders](/diseases/white-matter-disorders)

Therapeutic Mechanisms

Clinical Development Pipeline

References